Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline…
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…